Certain directors of GNC Holdings Inc are under investigation concerning potential wrongdoing. The investigation was announced for current long-term investors in NYSE:GNC shares concerning potential breaches of fiduciary duties by certain directors of GNC Holdings Inc.
Investors who are current long term investors in GNC Holdings Inc (NYSE:GNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm for current long term investors in NYSE:GNC stocks follows a lawsuit filed recently against GNC Holdings over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE:GNC stocks, concerns whether certain GNC Holdings directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Oregon the plaintiff alleges that the Defendants issued certain materially false and misleading statements to investors and/or failed to disclose that GNC Holdings unlawfully sold thousands of units of products in Oregon that contained picamilon, that GNC Holdings unlawfully sold thousands of units of products in Oregon that contained BMPEA, and that as a result of the foregoing, GNC Holdings’ public statements were materially false and misleading at all relevant times.
On February 3, 2015, the New York Attorney General Eric Schneiderman announced that his office sent letters to four major retailers, GNC Holdings Inc, Target, Walmart, and Walgreens, for allegedly selling store brand herbal supplement products in New York that either could not be verified to contain the labeled substance, or which were found to contain ingredients not listed on the labels. The letters, sent Monday, call for the retailers to immediately stop the sale of certain popular products, including Echinacea, Ginseng, St. John’s Wort, and others. Shares of GNC Holdings Inc (NYSE:GNC) declined to as low as $41.43 per share on February 3, 2015.
On February 4, 2015, GNC Holdings Inc announced that it will voluntarily comply with the New York State Attorney General’s letter of February 2 by temporarily removing from its stores in New York the product lots cited in the letter.
On October 22, 2015, the State of Oregon sued GNC Holdings Inc, claiming that the company’s nutritional and dietary supplements are laced with unapproved drugs, including picamilon and BMPEA.
According to the complaint GNC Holdings Inc violated the Oregon Unlawful Trade Practices ACT (“UTPA”) by misrepresenting some of its products as lawful dietary supplements. The complaint alleges that certain products that were misrepresented are unapproved drugs that may not be lawfully sold in the United States as a dietary supplement. In addition, the complaint alleged that GNC Holdings Inc sold products labeled containing botanical acacia rigidula that were added with unlabeled BMPEA and that GNC Holdings Inc allegedly sold thousands of units of products containing picamilon or BMPEA that were falsely labeled as a dietary supplement.
On the same day, GNC Holdings Inc responded to the claims made by the Oregon Attorney General and issued a statement saying that the claims made by the Oregon Attorney General are without merit and GNC Holdings Inc intends to vigorously defend against these allegations.
GNC Holdings Inc also said that in response to FDA statements regarding the regulatory status of BMPEA and picamilon, GNC Holdings Inc promptly took action to remove from sale all products containing those ingredients. Shares of GNC Holdings Inc (NYSE:GNC) declined to as low as $23.13 per share on January 19, 2016.
On April 5, 2016, NYSE:GNC shares closed at $30.55 per share.
Those who purchased NYSE:GNC shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com